AbbVie Inc. (ABBV) may enjoy gains as insiders got busy in the recent days


AbbVie Inc.’s filing revealed that its Vice Chairman SEVERINO MICHAEL unloaded Company’s shares for reported $12.04 million on May 23. In the deal valued at $150.90 per share,79,801 shares were sold. As a result of this transaction, SEVERINO MICHAEL now holds 152,103 shares worth roughly $ 22.1 million.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Then, SEVERINO MICHAEL sold 100,000 shares, generating $15,404,400 in total proceeds. Upon selling the shares at $154.04, the Vice Chairman now owns 152,103 shares.

Before that, Gosebruch Henry O sold 83,960 shares. AbbVie Inc. shares valued at $13,013,800 were divested by the EVP, Chief Strategy Officer at a price of $155.00 per share. As a result of the transaction, Gosebruch Henry O now holds 16,623 shares, worth roughly $2.41 million.

Atlantic Equities downgraded its AbbVie Inc. [ABBV] rating to a Neutral from a an Overweight in a research note published on Friday, August 01, 2022; the price target was decreased to $162 from $178. PT values the company’s stock at a premium of 10.32 to its Friday closing price. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who began to cover the stock in late May with a ‘”an Underperform”‘ rating. Daiwa Securities also remained covering ABBV and has decreased its forecast on May 06, 2022 with a “Neutral” recommendation from previously “an Outperform” rating.

Price Performance Review of ABBV

On Friday, AbbVie Inc. [NYSE:ABBV] saw its stock jump 0.60% to $145.28. On the same session, the stock had its day’s lowest price of $143.08, but rose to a high of $145.58. Over the last five days, the stock has lost -1.58%. AbbVie Inc. shares have risen nearly 7.30% since the year began. Nevertheless, the stocks have risen 24.11% over the past one year. While a 52-week high of $175.91 was reached on 04/08/22, a 52-week low of $115.01 was recorded on 01/24/22. SMA at 50 days reached $142.19, while 200 days put it at $147.57. A total of 4.62 million shares were traded, compared to the trading of 3.85 million shares in the previous session.

Levels Of Support And Resistance For ABBV Stock

The 24-hour chart illustrates a support level at 143.71, which if violated will result in even more drops to 142.15. On the upside, there is a resistance level at 146.21. A further resistance level may holdings at 147.15. The Relative Strength Index (RSI) on the 14-day chart is 50.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.57%. Stochastics %K at 21.76% indicates the stock is a holding.

How much short interest is there in AbbVie Inc.?

A steep rise in short interest was recorded in AbbVie Inc. stocks on Jul 14, 2022, growing by 0.51 million shares to a total of 14.03 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 13.52 million shares. There was a rise of 3.64%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 0.79% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.22.

AbbVie Inc. [ABBV] – Who Are The Largest Shareholders?

In filings from The Vanguard Group, Inc., it is revealed that the company now owns 146,064,918 shares, or roughly 8.26% of the outstanding ABBV shares. In other words, the investor’s shares have risen by 2,890,797 from its previous 13-F filing of 143174121.0. Additionally, BlackRock Fund Advisors increased 5.43% of its stake after which the total value it holdings stand at $11,421,824,482, while SSgA Funds Management, Inc. reduced -1.18% of its stake to hold $10.35 billion in the firm. Over the last quarter, Capital Research & Management Co purchased 12,657,354 shares of AbbVie Inc., while JPMorgan Investment Management, I bought 1,632,147 shares. At present, T. Rowe Price Associates, Inc. is holding 30,807,798 shares valued at $4.13 billion. Geode Capital Management LLC owned 30,081,427 shares of the company at the time of its most recent 13F filing, worth $4.04 billion.


Please enter your comment!
Please enter your name here